These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 25096867)
1. Respiratory failure during infusion of pamidronate in a 3 year-old male with osteogenesis imperfecta: a case report. Olson JA J Pediatr Rehabil Med; 2014; 7(2):155-8. PubMed ID: 25096867 [TBL] [Abstract][Full Text] [Related]
2. Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta. Munns CF; Rauch F; Mier RJ; Glorieux FH Bone; 2004 Jul; 35(1):231-4. PubMed ID: 15207762 [TBL] [Abstract][Full Text] [Related]
3. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment. Land C; Rauch F; Travers R; Glorieux FH Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117 [TBL] [Abstract][Full Text] [Related]
4. Low-dose intravenous pamidronate treatment in osteogenesis imperfecta. Gökşen D; Coker M; Darcan S; Köse T; Kara S Turk J Pediatr; 2006; 48(2):124-9. PubMed ID: 16848111 [TBL] [Abstract][Full Text] [Related]
6. Cyclical intravenous pamidronate treatment affects metaphyseal modeling in growing patients with osteogenesis imperfecta. Land C; Rauch F; Glorieux FH J Bone Miner Res; 2006 Mar; 21(3):374-9. PubMed ID: 16491284 [TBL] [Abstract][Full Text] [Related]
7. Pamidronate treatment of children with moderate-to-severe osteogenesis imperfecta: a note of caution. Alharbi M; Pinto G; Finidori G; Souberbielle JC; Guillou F; Gaubicher S; Le Merrer M; Polak M Horm Res; 2009 Jan; 71(1):38-44. PubMed ID: 19039235 [TBL] [Abstract][Full Text] [Related]
8. Intravenous pamidronate treatment in children with moderate-to-severe osteogenesis imperfecta started under three years of age. Alcausin MB; Briody J; Pacey V; Ault J; McQuade M; Bridge C; Engelbert RH; Sillence DO; Munns CF Horm Res Paediatr; 2013; 79(6):333-40. PubMed ID: 23735642 [TBL] [Abstract][Full Text] [Related]
9. Osteogenesis imperfecta, current and future medical treatment. Rauch F; Glorieux FH Am J Med Genet C Semin Med Genet; 2005 Nov; 139C(1):31-7. PubMed ID: 16278881 [TBL] [Abstract][Full Text] [Related]
10. Effects of bisphosphonates on tooth eruption in children with osteogenesis imperfecta. Kamoun-Goldrat A; Ginisty D; Le Merrer M Eur J Oral Sci; 2008 Jun; 116(3):195-8. PubMed ID: 18471236 [TBL] [Abstract][Full Text] [Related]
11. [Bone and joint diseases in children. Bisphosphonates in osteogenesis imperfecta]. Yamashita S Clin Calcium; 2010 Jun; 20(6):918-24. PubMed ID: 20513950 [TBL] [Abstract][Full Text] [Related]
12. Large osteoclasts in pediatric osteogenesis imperfecta patients receiving intravenous pamidronate. Cheung MS; Glorieux FH; Rauch F J Bone Miner Res; 2009 Apr; 24(4):669-74. PubMed ID: 19063679 [TBL] [Abstract][Full Text] [Related]
13. Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta. Rauch F; Cornibert S; Cheung M; Glorieux FH Bone; 2007 Apr; 40(4):821-7. PubMed ID: 17223617 [TBL] [Abstract][Full Text] [Related]
14. Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy. Arikoski P; Silverwood B; Tillmann V; Bishop NJ Bone; 2004 Mar; 34(3):539-46. PubMed ID: 15003801 [TBL] [Abstract][Full Text] [Related]
15. The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta type V. Zeitlin L; Rauch F; Travers R; Munns C; Glorieux FH Bone; 2006 Jan; 38(1):13-20. PubMed ID: 16162424 [TBL] [Abstract][Full Text] [Related]
16. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. DiMeglio LA; Peacock M J Bone Miner Res; 2006 Jan; 21(1):132-40. PubMed ID: 16355282 [TBL] [Abstract][Full Text] [Related]